SecBot SecBot

PTGX

Protagonist Therapeutics, Inc
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001377121 Biotech & Drug Discovery
$124.83 −6.12 (−4.67%)
Nov 16 4:00 PM ET · prev $130.95
Market cap
$8.8B
Mid cap
Consensus
Buy
95% Buy or better · 21 analysts
Median target
$181.00
+45% · range $151.00–225.00
1 year
+47.3%
from $84.77 · Nov 17
30 days
−7.1%
from $134.44
52-week range
$79.73–158.62
−21% from high · low Jan 29
Avg volume 20D
603.1K
shares / day
Short interest
10.24M
≈15.7% of shares · −0.5%
Days to cover
16.9
at average volume
Insider net
−$71.9M
0 buyers · 6 sellers · 12 mo
New fund stakes
2
Q3 2026 13F · 1 exit
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Feb 6 ▼ 1 insider sell $1.7M at $83.68
  • Mar 24 to Mar 26 ▼ 3 days of insider sells: $12.2M by 4 insiders, avg $102.97
  • Apr 20 ▼ 1 insider sell $184.6K at $105.47
  • May 7 to May 12 ▼ 3 days of insider sells: $13.4M by 2 insiders, avg $100.11
  • May 29 ▼ 1 insider sell $896.8K at $99.64
  • Jun 10 ▼ 1 insider sell $969.1K at $107.68
  • Jun 23 ▼ 1 insider sell $1.1M at $117.94
  • Aug 10 to Aug 11 ▼ 2 days of insider sells: $14.9M by 1 insider, avg $148.91
  • Sep 8 to Sep 10 ▼ 3 days of insider sells: $18.2M by 1 insider, avg $145.92
  • Sep 30 ▼ 1 insider sell $8.3M at $141.78
  • Oct 12 UBS initiates
  • Nov 5 ▲ Protagonist Therapeutics reported Q3 2026 net income of $220.0M ($3.…

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $71.9M.

  • InstitutionsBULLISH

    Q3 2026: 38 added (2 new), 18 trimmed or exited. Largest new: Renaissance Technologies $10.8M.

  • AnalystsBULLISH

    20 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −0.5% to 10.24M shares. 16.9 days to cover, ≈15.7% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
1
exit
$10.8M
in new stakes · top 1 shown
FundMoveSharesValue
FMR LLCADD1,075,869$151.6M
JPMORGAN CHASE & COADD342,802$48.7M
PUBLIC SECTOR PENSION INVESTMENT BOARDADD325,881$45.2M
Russell Investments Group, Ltd.ADD214,777$30.3M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED112,923$15.9M
FIRST TRUST ADVISORS LPADD89,979$12.7M
TD ASSET MANAGEMENT INCTRIM85,750$12.1M
MANUFACTURERS LIFE INSURANCE COMPANY, THETRIM80,529$11.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy13Hold1Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +45%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 21, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 12, 2026UBS
INITIATE
INITIATEBuy
Sep 1, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 1, 2026BMO Capital
MAINTAIN
MAINTAINOutperform
Aug 31, 2026Citigroup
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$71.9M
sold · 6 insiders
DateInsiderTypeValue
Sep 30, 2026
Ali Asif
Chief Financial Officer
Sep 30, 2026
EXERCISE$666.0K
Sep 30, 2026
Ali Asif
Chief Financial Officer
Sep 30, 2026
EXERCISE$300.3K
Sep 30, 2026
Ali Asif
Chief Financial Officer
Sep 30, 2026
EXERCISE$64.6K
Sep 30, 2026
Ali Asif
Chief Financial Officer
Sep 30, 2026
EXERCISE$359.7K
Sep 30, 2026
Ali Asif
Chief Financial Officer
Sep 30, 2026
SELL$1.8M
Sep 30, 2026
Ali Asif
Chief Financial Officer
Sep 30, 2026
SELL$6.5M
Sep 10, 2026
PATEL DINESH V PH D
President and CEO
Sep 10, 2026
EXERCISE$157.1K
Sep 10, 2026
PATEL DINESH V PH D
President and CEO
Sep 10, 2026
SELL$1.0M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.36-$0.35–$1.85+387.8%$58.3M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
10,242,340
shares short
-0.5%
vs prior settlement
16.9
days to cover
≈15.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 SEC
Protagonist Therapeutics reported Q3 2026 net income of $220.0M ($3.07 diluted EPS) on $274.4M in license and…
8-K · Impact 7/10
Nov 4, 2026 SEC
In Q3 2026, five asset managers added to their PTGX positions totaling $7.2M in net buying, while two sellers reduced…
INST-CLUSTER · Impact 3/10
Nov 4, 2026 Earnings calendar
PTGX Q3 2026 Earnings After Market Close · 2026-11-04
Oct 27, 2026 SEC
BlackRock filed an amended Schedule 13G disclosing beneficial ownership of 9,834,146 shares of Protagonist…
SC 13G/A · Impact 3/10
Sep 30, 2026 Insider
Ali Asif acquired via exercise 28,438 shares
Chief Financial Officer @ $23.42 ($666.0K)
Sep 30, 2026 Insider
Ali Asif acquired via exercise 15,650 shares
Chief Financial Officer @ $19.19 ($300.3K)
Sep 30, 2026 Insider
Ali Asif acquired via exercise 5,312 shares
Chief Financial Officer @ $12.17 ($64.6K)
Sep 30, 2026 Inst.
FMR LLC · ADD
1,075,869 shares ($151.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent
Nov 4, 2026
Earnings date
PTGX Q3 2026 Earnings After Market Close · 2026-11-04
Aug 4, 2026
Earnings date
PTGX Q2 2026 Earnings After Market Close, 2026-08-04
May 12, 2026
Short interest
FTD: PTGX, 10,792 shares ($1.1M) failed to deliver
Settlement: 20260512, Price: $103.50, FTD Value: $1,116,972, PROTAGONIST THERAPEUTICS INC C
May 8, 2026
Short interest
FTD: PTGX, 31,241 shares ($3.1M) failed to deliver
Settlement: 20260508, Price: $98.85, FTD Value: $3,088,172.85, PROTAGONIST THERAPEUTICS INC C
May 4, 2026
Earnings date
PTGX Q1 2026 Earnings After Market Close, 2026-05-04

SecBot reports

11 filings · 2 bullish · 2 bearish · 3 mixed · 4 neutral
All PTGX filing & press-release reports (11)